The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.
|Original language||English (US)|
|Title of host publication||AAPS Advances in the Pharmaceutical Sciences Series|
|Number of pages||40|
|State||Published - 2022|
|Name||AAPS Advances in the Pharmaceutical Sciences Series|
Bibliographical noteFunding Information:
Acknowledgments This work was supported by the National Institutes of Health [Grants RO1 NS107548, U54 CA210180, U01 CA227954]. The authors would also like to thank the editors of the book for their comments and valuable inputs.
© 2022, American Association of Pharmaceutical Scientists.
- Active transporters
- Antibody drug conjugates
- Blood-tumor barrier
- Receptor mediated transport